Oseltamivir induced sinus bradycardia: an area of potential concern

Authors

  • Karan B. Shah Department of Pharmacology, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India
  • Bhavesh S. Shah Director, Pooja Hospital, Opp. New bus stand, Kapadwanj, Gujarat 387620, India
  • Supriya D. Malhotra Head, Department of Pharmacology, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India
  • Pankaj R. Patel Dean, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20185177

Keywords:

Bradycardia, H1N1, Oseltamivir, Swine flu

Abstract

Oseltamivir was approved for the prevention and treatment of influenza in 1999 by the USFDA (US Food and Drug Administration). The use of Oseltamivir is increasing rapidly all over the world, especially after the 2009 “Swine Flu” pandemic. Less data is published as far as the cardiovascular side effects of Oseltamivir are concerned, but it could be associated with some serious cardiovascular side effects. This study presented a case series of 5 cases suspected to be suffering from seasonal influenza H1N1 (“Swine Flu”), who developed sinus bradycardia while they were on Oseltamivir therapy.

References

Oseltamivir phosphate, American Journal of Health-System Pharmacy February 2000;57(3)282. (Retrieved January 8, 2017). Available at: http://www.ajhp.org/content/57/3/282

488 swine flu deaths reported in Maharashtra between January and August (accessed on September 4,2017) Available at: http://www.asianage.com/metros/mumbai/040917/488-swine-flu-deaths-reported-in-maharashtra-between-january-and-august.html)

H1N1 has killed 1,100 so far this year (accessed on September 4,2017). Available at: http://timesofindia.indiatimes.com/lifestyle/healthfitness/health-news/h1n1-has-killed-1100-so-far-this year/articleshow/60335224.cms)

Barclay WS. Influenza: a world of discoveries, outbreaks and controversy. J Gen Virol. 2017 May 24;98(5):892-4.

Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4(4):CD008965. (PMID 24718923).

Rossi S. Australian Medicines Handbook. 7th ed. Sydney; 2006:143-145.

VigiAccessTM. Accessed on September 4,2017, at http://www.vigiaccess.org/ Available at: http://www.vigiaccess.org/. Accessed 4 September 2017.

eHealthMeTM. Accessed on September 4,2017, at http://www.ehealthme.com/ds/tamiflu/bradycardia/. Available at: http://www.ehealthme.com/ds/tamiflu/bradycardia/. Accessed 4 September 2017.

CD Alert, Monthly Newsletter of National Centre for Disease Control, Directorate General of Health Services, Government of India. Aug - Sept 2009;13:No. 2.

Sağcan A, Tümüklü MM, Şekuri C, Sağcan M, Selçuk OD, Zungur M, et al. PP-204 [AJC» Cardiac pacing for bradyarrhythmias] Extreme Bradycardia (Standstill) Case Due to Oseltamivir Use (A rare side effect). The Ame J Cardiol. 2017 Apr 15;119(8):e95.

Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicro Chemoth. 2010 Apr 1;65(suppl_2):ii5-10.

Frommeyer G, Mittelstedt A, Wolfes J, Ellermann C, Kochhäuser S, Leitz P, et al. The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model. Naunyn-Schmiedeberg's archives of pharmacology. 2017 Nov 1;390(11):1155-61.

Downloads

Published

2018-12-24

How to Cite

Shah, K. B., Shah, B. S., Malhotra, S. D., & Patel, P. R. (2018). Oseltamivir induced sinus bradycardia: an area of potential concern. International Journal of Basic & Clinical Pharmacology, 8(1), 162–165. https://doi.org/10.18203/2319-2003.ijbcp20185177

Issue

Section

Case Reports